tradingkey.logo
搜索

MaxCyte Inc

MXCT
添加自选
1.215USD
-0.015-1.22%
收盘 07/02, 13:00美东报价延迟15分钟
130.15M总市值
亏损市盈率 TTM

MaxCyte Inc

1.215
-0.015-1.22%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.22%

5天

-4.33%

1月

-1.22%

6月

-21.61%

今年开始到现在

-21.61%

1年

-45.76%

关键数据
1.250今开
1.275最高
813.34K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.76%换手率
1.230昨收
1.190最低
567.45K成交额
亏损市盈率静
0.78市净率
0.00%股息率 TTM
-18.43%ROA
2.40052周最高
0.40量比
-41.05M净利润
107.12M总股本
-0.3669每股收益TTM
1.45Beta
-21.30%ROE
0.64352周最低
6.91%振幅
73.22%毛利率
130.15M总市值
0.61回报/风险
4.11%风险率

TradingKey MaxCyte Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

MaxCyte Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名97/204位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价4.11。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

MaxCyte Inc评分

相关信息

行业排名
97 / 204
全市场排名
228 / 4565
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

MaxCyte Inc亮点

亮点风险
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
业绩增长期
公司处于发展阶段,最新年度总收入33.03M美元
利润高增长
公司净利润处于行业前列,最新年度总收入33.03M美元
估值高估
公司最新PE估值-3.31,处于3年历史高位
机构减仓
最新机构持股79.92M股,环比减少19.15%
活跃度增加
近期活跃度增加,过去20天平均换手率0.80

分析师目标

根据 7 位分析师
买入
评级
4.107
目标均价
+231.25%
涨幅空间

MaxCyte Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

MaxCyte Inc简介

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
公司代码MXCT
公司MaxCyte Inc
CEOMasoud (Maher)
网址https://www.maxcyte.com/

常见问题

MaxCyte Inc(MXCT)的当前股价是多少?

MaxCyte Inc(MXCT)的当前股价是 1.22。

MaxCyte Inc的股票代码是什么?

MaxCyte Inc的股票代码是MXCT。

MaxCyte Inc股票的52周最高点是多少?

MaxCyte Inc股票的52周最高点是2.40。

MaxCyte Inc股票的52周最低点是多少?

MaxCyte Inc股票的52周最低点是0.64。

MaxCyte Inc的市值是多少?

MaxCyte Inc的市值是130.15M。

现在MaxCyte Inc(MXCT)的股票是买入、持有还是卖出?

根据分析师评级,MaxCyte Inc(MXCT)的总体评级为买入,目标价格为4.11。

MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是多少

MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是-0.42。